Inventor
PINTER ABRAHAM
US14 patents
⚠️ This page may combine multiple inventors who share the name “PINTER ABRAHAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV RUTGERS
6 patentsUS11273220B2Mar 15, 2022
Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
UNIV RUTGERS1 citations71
US10729771B2Aug 4, 2020
Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
UNIV RUTGERS1 citations71
US11707525B2Jul 25, 2023
Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
UNIV RUTGERS0 citations54
US12303562B2May 20, 2025
Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
UNIV RUTGERS0 citations51
US9938325B2Apr 10, 2018
HIV-1 antigens with discrete conformational forms in the V1/V2 domain and methods of use thereof
UNIV RUTGERS0 citations51
US9796773B2Oct 24, 2017
Neutralizing antibodies that bind to the HIV-1 Env V2 critical neutralization domain
UNIV RUTGERS0 citations51
NEW YORK HEALTH RES INST
5 patentsUS6815201B2Nov 9, 2004
HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
NEW YORK HEALTH RES INST104 citations97
US5643756AJul 1, 1997
Fusion glycoproteins
NEW YORK HEALTH RES INST66 citations92
US5616459AApr 1, 1997
Selection of ribozymes that efficiently cleave target RNA
NEW YORK HEALTH RES INST67 citations91
US5952474ASep 14, 1999
Fusion glycoproteins
NEW YORK HEALTH RES INST32 citations89
US5922325AJul 13, 1999
Synergistic neutralization of HIV-1 by human monoclonal antibodies and other antibodies directed against the v3 loop and the CD-4 binding site of GP-120,and the use for immunotherapy of HIV-1 infection
NEW YORK HEALTH RES INST29 citations86